Hayakawa Ikuko, Shirasaki Fumiaki, Hirano Takashi, Oishi Naoto, Hasegawa Minoru, Sato Shinichi, Takehara Kazuhiko
Department of Dermatology, Kanazawa University Graduate School of Medical Science , 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan.
Rheumatol Int. 2006 Jan;26(3):270-3. doi: 10.1007/s00296-005-0613-y. Epub 2005 May 25.
We describe two systemic sclerosis (SSc) patients with isolated pulmonary arterial hypertension (PAH) who were given treatment with 50 mg oral sildenafil per day. We evaluated the efficacy of oral sildenafil for isolated PAH in SSc patients by direct assessment with cardiac catheterization before and 6 months after the initiation of sildenafil. Right-heart catheterization demonstrated decreased mean pulmonary artery pressure, decreased pulmonary vascular resistance, and increased cardiac output after treatment with sildenafil. Brain natriuretic peptide levels were gradually decreased. The 6-min walking distance was greatly extended. Moreover, the physical conditions of both patients were much improved. We recognized no adverse events. We propose that oral sildenafil may be beneficial as a selective pulmonary vasodilator and as long-term treatment in SSc patients with isolated PAH.
我们描述了两名患有孤立性肺动脉高压（PAH）的系统性硬化症（SSc）患者，他们接受了每天50毫克口服西地那非的治疗。我们通过在开始使用西地那非之前和之后6个月进行心脏导管插入术直接评估，来评价口服西地那非对SSc患者孤立性PAH的疗效。右心导管插入术显示，使用西地那非治疗后平均肺动脉压降低、肺血管阻力降低且心输出量增加。脑钠肽水平逐渐下降。6分钟步行距离大幅延长。此外，两名患者的身体状况均有显著改善。我们未发现不良事件。我们认为口服西地那非作为一种选择性肺血管扩张剂，对于患有孤立性PAH的SSc患者可能是一种有益的长期治疗药物。
